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Abstract
Background: Obesity and low high-density lipoprotein-cholesterol (HDL-C) levels are associated with cardiovascular
risk. Surprisingly, despite a greater prevalence of obesity and lower HDL concentrations than white women, black
South African women are relatively protected against ischaemic heart disease.
Methods: We investigated whether this apparent discrepancy may be related to different HDL function and subclass
distribution in black and white, normal-weight and obese South African women (n = 40). HDL functionality was assessed
by measuring paraoxonase (PON) activity, platelet activating factor acetylhydrolase (PAF-AH) activity, Oxygen Radical
Absorbance Capacity (ORAC) and quantification of the expression of vascular cell adhesion molecule in endothelial cells.
PON-1 and PAF-AH expression was determined in isolated HDL and serum using Western blotting. Levels of large,
intermediate and small HDL subclasses were measured using the Lipoprint® system.
Results: PON activity was lower in white compared to black women (0.49 ± 0.09 U/L vs 0.78 ± 0.10 U/L, p < 0.05),
regardless of PON-1 protein levels. Obese black women had lower PAF-AH activity (9.34 ± 1.15 U/L vs 13.89 ± 1.21 U/L, p
<0.05) and HDL-associated PAF-AH expression compared to obese white women. Compared to normal-weight women,
obese women had lower large HDL, greater intermediate and small HDL; an effect that was more pronounced in
white women than black women. There were no differences in antioxidant capacity or anti-inflammatory function
across groups.
Conclusions: Our data show that both obesity and ethnicity are associated with differences in HDL functionality,
while obesity was associated with decreases in large HDL subclass distribution. Measuring HDL functionality and
subclass may, therefore, be important factors to consider when assessing cardiovascular risk.
Keywords: High-density lipoprotein, Ethnicity, Obesity, Cardiovascular risk
Background
Although the leading cause of death in Sub-Saharan
Africa remains communicable diseases, the prevalence
of ischemic heart disease is increasing and it is pre-
dicted to be the leading cause of death in low-income
countries by 2030 [1–3]. The changes in standardized
health care, progressive changes in socio-economic status
and greater Westernization have raised the burden of pre-
ventable cardiovascular diseases (CVD) [4–6]. In addition,
nearly 23 % of the worldwide burden of ischaemic heart
disease can be attributed to obesity, the prevalence of
which has doubled since 1980 [7]. Obesity is associated
with insulin resistance, which may increase the risk of type
II diabetes and dyslipidaemia, as evidenced by an increase
in triglycerides and low-density lipoproteins cholesterol
(LDL-C) and a decrease in high-density lipoproteins chol-
esterol (HDL-C) in these patients [8–11].
Ethnic differences in lipid profiles and CVD risk have
been documented, attributed to, in part, genetic, socio-
economic and lifestyle differences [5, 12]. Black South
* Correspondence: nicholaswoudberg@gmail.com
1Department of Medicine, Hatter Institute for Cardiovascular Research in
Africa and South African Medical Research Council Inter-University Cape
Heart Group, Faculty of Health Sciences, University of Cape Town, Chris
Barnard Building, Anzio Road, Observatory, 7925 Cape Town, Western Cape,
South Africa
Full list of author information is available at the end of the article
© 2016 Woudberg et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Woudberg et al. Lipids in Health and Disease  (2016) 15:92 
DOI 10.1186/s12944-016-0257-9
African women and African Americans exhibit protect-
ive lipid profiles, characterised by low LDL-C, low trigly-
ceride and low total cholesterol concentrations [13, 14].
In addition, cholesterol-attributable mortality is higher
in South African white compared to black populations,
with only 1.8 % mortality attributable to ‘sub-optimal’
cholesterol levels in black populations [15]. It was previ-
ously thought that a favourable lipid profile in black popu-
lations would also be characterised by higher HDL-C
concentrations [16, 17]. However, recent studies conducted
in black South African women highlighted a lower or
equivalent level of HDL-C than their white counterparts
[6, 12, 14, 18].
The Framingham Heart study suggests an inverse rela-
tionship between HDL-C levels and cardiovascular risk
[19]. However, recent clinical trials aiming to reduce
cardiovascular complications by raising HDL-C levels
have shown disappointing results [20, 21]. Elucidation of
the complexity of the HDL molecule, has led to a shift
from measuring the quantity of HDL-C to assessing the
composition, the distribution of individual HDL sub-
classes and HDL functionality to try to explain the rela-
tionship between HDL and cardiovascular risk [22, 23].
The risk of ischemic heart disease in African populations
has largely been defined by classical risk factors, including
the cholesterol component of HDL. Given the prevailing
doubts about the cardiovascular value of HDL-C, the
present study used blood collected from a population of
black and white, obese and normal-weight South African
women, to explore whether ethnicity and obesity may be




The sample population consisted of 40 normal-weight
(Body Mass Index [BMI] 18–24.9 kg/m2) and obese
(BMI > 30 kg/m2) self-reported black and white South
African women, who had been enrolled for previous stud-
ies and described in detail [18, 24]. Inclusion criteria in-
cluded (1) age from 18 to 45 years; (2) no known diseases
or taking medication for dyslipidemia, diabetes, hyperten-
sion, HIV/AIDS or any other metabolic disorders; and (3)
not currently pregnant, lactating or postmenopausal. The
study was approved by the Research Ethics Committee of
the Faculty of Health Sciences of the University of Cape
Town.
Basic anthropometric measurements, including height
and weight, were taken. Body fat percentage was mea-
sured using dual-energy x-ray absorptiometry, while vis-
ceral and abdominal subcutaneous adipose tissue were
measured using computed tomography as previously de-
scribed [18]. Fasting serum samples were taken and
stored at −80 °C prior to use.
Biochemical measurements
HDL isolation
HDL was isolated from 200 μl aliquots of serum as follows:
Serum samples were added to a mixture containing 1 part
500iu/ml heparin (Mucosal, Fresenius) and 2 parts 1.12
(mol/L) manganese chloride solution. Samples were centri-
fuged at 10 000 g for 1 h at 4 °C. The supernatant was dia-
lysed against phosphate buffered saline (PBS, pH 7.4) in
Spectra/Por 2 RC membrane (12 000–14 000 kDa) (GIC
Scientific, 132676) and 200 μl aliquots were then dissolved
in sodium bromide (275.5 mg/ml of supernatant), trans-
ferred to thick-wall polycarbonate ultracentrifuge tubes
(Beckman, 343775) and centrifuged at 223 000 g for 20 h
at 4 °C and the upper 70 μl layer was extracted. Purity was
confirmed using 12.5 % reducing SDS-polyacrylamide gel
electrophoresis (PAGE) stained with Coomassie Blue. The
protein concentration of HDL was determined by the
modified Lowry method [25]. All samples were analysed in
duplicate.
Paraoxonase (PON) activity assay
Serum samples were diluted 1:10 in phosphate buffer
containing 2 mmol/L CaCl2 (pH 8). Diluted serum was
added to 96-well plates in triplicate and paraoxon-ethyl
substrate (Sigma, D9286) was added. Absorbance at A405
was measured at 30 s intervals over 20 min. One Unit of
activity is defined as 1 nmol of substrate hydrolysed per
minute.
Platelet Activating Factor Acetylhydrolase (PAF-AH) activity
assay
PAF-AH activity was measured in participant sera using
the PAF Acetylhydrolase Assay Kit (Cayman Chemical,
760901). Briefly, serum was added to an equal volume of
5, 5′-dithio-bis-(2-nitrobenzoic acid) (DTNB; Ellman’s
Reagent) and assay buffer in triplicate into clear 96-well
plates. All wells were incubated with 2-thio PAF sub-
strate and absorbance at A412 measured at 1 min time
intervals for 20 min. One Unit of activity is defined as
1 μmol of substrate hydrolysed per minute.
Western blotting
Isolated HDL and serum samples from each of the par-
ticipants were electrophoresed on reducing 12.5 % SDS-
polyacrylamide (SDS-PAGE) gels with 1.5 μg of HDL
protein or 8 ug of serum loaded per well. Samples were
run over three separate gels with control samples repeated
in each gel. Blots were transferred onto nitrocellulose
membranes (Bio-Rad, 162-0113). Ponceau S staining
was used to validate equal loading of wells. Blots
were blocked in 5 % low fat milk powder in 0.05 %
Tween in Tris-buffered Saline (TTBS, pH 7.5) and
incubated overnight in primary mouse anti-PON-1
antibody (1:200) [26] and rabbit anti-PAF-AH (1:400)
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(Cayman Chemical, 160603). Blots were then washed in
TTBS and incubated in goat anti-mouse-HRP conju-
gated secondary antibody (1:5000) (Bio-Rad, 170 6516)
and goat anti-rabbit-HRP conjugated secondary antibody
(1:2500) (Santa Cruz Biotechnology, sc-2313), respectively
for 1 h at room temperature. Blots were thoroughly
washed in TTBS prior to incubation in Amersham TM
ECL™ Western blotting detection reagent (GE Healthcare,
RPN2106). Blots were captured in the GeneGnome gel
imager. Densitometry of PON-1 and PAF-AH blots was
quantified using Quantity one software. PON-1 and PAF-
AH relative expression data were corrected for control
samples, repeated in each gel.
Oxygen Radical Absorbance Capacity (ORAC) Assay
Isolated HDL samples were diluted (1:50) in phosphate
buffer (pH 7.4) prior to analysis for the ORAC assay [27].
Briefly, a trolox standard curve of 0.078 nmol/L to
10 nmol/L was prepared. Fluorescein (3′, 6′ – dihydroxy-
spiro[isoberyofuran – 1[3H], 9′[9H] – xanthen] – 3-one)
and AAPH (2,2′ – azobis (2-amidinopropane) dihy-
drochloride) were prepared fresh in phosphate buffer. The
working fluorescein solution of fluorescein was 95.7 nmol/
L and AAPH equated to 32.1 μmol/L per well. Fifty μl of
trolox standards and HDL samples were added to wells in
white 96-well plates (AEC-Amersham) along with AAPH
and fluorescein. Fluorescence was measured over time
using the Varian Cary Eclipse fluorescence spectropho-
tometer (Varian Australia Pty Ltd) (Excitation wavelength
485 nm, Emission wavelength 520 nm). Data were
expressed as Trolox equivalents per volume.
Quantification of HDL anti-inflammatory function
Human umbilical vein endothelial cells (HUVEC) were
purchased from Lonza and were cultured in T75 culture
flasks according to supplier specifications. For experimen-
tal tests, 30 000 cells were seeded into 12-well culture
plates and cultured in RPMI-1640 media supplemented
with 20 % foetal calf serum (Biochrom BC/S0615), 1 ng/
mL vascular endothelial growth factor (VEGF) (Sigma,
V7259) and penicillin/streptomycin (Biowest, L0018). Five
hours after seeding, the medium was changed and supple-
mented with HDL isolated according to optimised proto-
col at 10 μg/mL. Cells were treated with HDL overnight
prior to stimulation with 20 ng/mL murine tumour necro-
sis factor alpha (TNF-α) (PeproTech, 315-01A) for 8 h.
Cell pellets were harvested and stored in RNA Protect
Cell Reagent (Qiagen, 76526) at −20 °C. RNA was isolated
using the RNeasy Micro kit (Qiagen, 74004) and cDNA
was synthesised using the High Capacity cDNA Reverse
Transcriptase Kit (Life Technologies, 4368814). cDNA
was quantified using the Qubit High Sensitivity RNA kit
(Qiagen, Q32852) and Qubit Fluorometer (LifeTechnologies).
cDNA was amplified for 25 cycles using the RT2 SYBR
Green qPCR kit (Qiagen, 330500) in the Rotor-
Gene6000 (Corbit Lifesciences) with the following
primers: VCAM-1 (sense), 5′-GAAGATGGTCGTGAT
CCTTG-3′ and (antisense), 5′-ACTTGACTGTGATCG
GCTTC-3′. GAPDH (sense), 5′-CCACCCATGGCAAA
TTCCATGGCA-3′ and (antisense), 5′-TCTAGACGGC
AGGTCAGGTCCACC-3′. Results indicate the mean of
at least 3 independent experiments ± SEM.
Quantification of HDL subclass distribution
Serum HDL subclass was determined using the Lipo-
print® HDL system (Quantimetrix, Redondo Beach, CA)
[28]. Briefly, serum (25 μl) was mixed with Lipoprint
loading gel (300 μl), containing Sudan black dye which
binds proportionally to the cholesterol present in the
sample. The mix was placed onto the upper part of the
high resolution 3 % polyacrylamide gel. Photopolymeri-
sation was carried out for 30 min at room temperature
and electrophoresis was performed for 50 min at 3 mA
per gel tube. After a rest period of 30 min, gel tubes
were scanned and analysed using the Lipoware software.
The VLDL and LDL remained at the origin [Retention
Factor (Rf ) = 0.0] while albumin migrated as the leading
front (Rf = 1.0). Between these, 10 HDL bands could be
detected. HDL-1, HDL-2 and HDL-3 were defined as
large HDL; HDL-4, HDL-5, HDL-6 and HDL-7 were de-
fined as intermediate HDL and HDL-8, HDL-9 and
HDL-10 were defined as small HDL. Each subclass was
quantified and expressed as a percentage of total HDL.
Statistical analysis
Results are presented as mean ± standard error of mean
(SEM). Two-way analysis of covariance, adjusting for
age, was used to compare paraoxonase activity, PAF-AH
activity, antioxidant capacity, relative VCAM expression
and HDL subclass distribution between normal-weight
and obese black and white women. Pearson correlation
coefficients were used to explore the relationships be-
tween measures of serum lipids, body composition and
HDL function and subclass.
Results
The body composition, lipid profiles and additional
physiological data of the participants have been previ-
ously published [18, 24] and summarised in Table 1.
In brief, ethnic differences included lower visceral adi-
pose tissue (VAT) and higher subcutaneous adipose
tissue (SAT) in obese black women compared to obese
white women. Critically, black women had lower HDL
and total cholesterol concentrations than their white
counterparts.
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PON activity in normal-weight and obese black and white
women
PON activity of normal-weight and obese, black and
white women is presented in Fig. 1a. Black women had
significantly higher PON activity levels than white women
(0.78 ± 0.10 U/L vs 0.49 ± 0.09 U/L, p < 0.05), with the ef-
fect being more pronounced in obese black women com-
pared to obese white women (0.84 ± 0.13 U/L vs 0.45 ±
0.14 U/L, p < 0.05) (Fig. 1a). Irrespective of ethnicity, PON
activity did not differ subject to obesity.
In order to explore whether differences in PON activity
levels were simply due to differences in PON-1 protein
expression in HDL, Western blotting was performed on
isolated HDL and serum. There were no significant differ-
ences in HDL-associated PON-1 protein levels between
black and white women, nor between normal-weight and
obese women (Fig. 1b and c). Similarly, there were no dif-
ferences in PON-1 serum expression between black and
white women, nor between normal-weight and obese
women (Fig. 1d and e). Full blot pictures are shown in
Additional file 1: Figure S1.
Table 2 shows that PON activity correlated positively
with LDL levels in both black and white women (p < 0.05),
positively with total cholesterol (p < 0.005) in black women
and negatively with total HDL (p < 0.005) in white women.
PAF-AH activity in normal-weight and obese black and
white women
There were no differences in PAF-AH activity between
black and white women, however, obese black women
had significantly lower PAF-AH activity levels than
obese white women (9.34 ± 1.15 U/L vs 13.89 ± 1.21 U/L,
p < 0.05) (Fig. 2a). PAF-AH activity did not differ subject
to obesity.
When examining PAF-AH protein expression in iso-
lated HDL, we found that obese black women had sig-
nificantly lower levels of HDL-associated PAF-AH than
obese white women (5.5 ± 1.7 vs 10.9 ± 1.8 Arbitrary
units, AU, p < 0.05) (Fig. 2b and c), which corresponds
to lower PAF-AH activity (r = 0.54, p < 0.005). However,
there were no differences between black and white obese
and normal-weight women in PAF-AH serum expression
(Fig. 2d and e). Full blots are shown in Additional file 1:
Figure S2.
PAF-AH was positively correlated with LDL (p < 0.005)
and total cholesterol (p < 0.005) concentrations in both
black and white women (Table 2). In black women only,
increased PAF-AH activity was associated with reduced
fat mass, SAT and triglyceride concentrations (p < 0.05).
Antioxidant capacity and anti-inflammatory function of
isolated HDL
No obesity-related or ethnic differences were observed for
the anti-inflammatory function and antioxidant capacity
of isolated HDL (Additional file 1: Figures S3 and S4).
HDL subclass distribution in normal-weight and obese
black and white women
Figure 3 shows the distribution of large, intermediate and
small HDL subclasses, quantified using the Lipoprint® sys-
tem. Scans (Fig. 3a) were quantified, producing unique
HDL subclass profiles (Fig. 3b–f ). HDL subclass distribu-
tion was different between obese and normal-weight
women with less large HDL (−10 %, p < 0.05) and signifi-
cantly more intermediate HDL (+6 %, p < 0.05) in the
obese compared to the normal-weight women (Fig. 3g),
which was largely driven by differences between the
normal-weight and obese white women (43.1 ± 3.4 % vs
Table 1 Characteristics and serum lipids of participants included in the study
White normal-weight (n = 12) White obese (n = 9) Black normal-weight (n = 8) Black obese (n = 11)
Age (yr) 26 ± 2 34 ± 2B, C 23 ± 2 27 ± 2
BMI (kg/m2) 22.6 ± 0.7 33.4 ± 0.8B, C 22.8 ± 0.9 38.5 ± 0.7D
Fat (kg) 19.2 ± 1.4 40.4 ± 1.6C 17.1 ± 1.7 44.9 ± 1.5D
Body fat (%) 29.5 ± 1.4 43.7 ± 1.6C 30.0 ± 1.7 46.7 ± 1.5D
VAT area (cm2) 62.2 ± 11.3 144.9 ± 13.1B, C 56.9 ± 13.9 95.6 ± 11.8D
SAT area (cm2) 187.0 ± 19.1 471.6 ± 22.0B, C 175.2 ± 23.4 594.2 ± 19.9d
Serum lipids
HDL cholesterol (mmol/L) 1.7 ± 0.1a 1.5 ± 0.1B 1.3 ± 0.1 1.0 ± 0.1
LDL cholesterol (mmol/L) 2.0 ± 0.2 2.5 ± 0.2 2.1 ± 0.2 2.1 ± 0.2
Triglycerides (mmol/L) 0.9 ± 0.1 1.0 ± 0.1 0.5 ± 0.1 0.8 ± 0.1
Total cholesterol (mmol/L) 4.1 ± 0.2 4.6 ± 0.3B 3.6 ± 0.3 3.5 ± 0.2
Values are unadjusted means ± SEM. All p values are adjusted for age
a p < 0.05 white normal-weight vs black normal-weight
B p < 0.01 white obese vs black obese
C p < 0.01 normal-weight vs obese white
d p < 0.05 and D p < 0.01 normal-weight vs obese black
Woudberg et al. Lipids in Health and Disease  (2016) 15:92 Page 4 of 11
32.8 ± 3.8 % for large HDL, p < 0.05) (Fig. 3g). There were
no differences in the percentages of small HDL subclasses
between groups.
In the white women, the greater proportion of large
HDL subclasses was associated with higher BMI, fat mass,










































































































Fig. 1 Paraoxonase activity and protein expression in white and black women. Paraxonase activity of diluted sera was measured at A405 over a 20 min
time interval using the paraoxon-ethyl substrate. One unit of activity is defined as 1 nmol of substrate disintegrated per minute (a). Isolated HDL (b–c)
and participant sera (d–e) were run on reducing 12.5 % SDS-PAGE gels and transferred to nitrocellulose membrane. Ponceau S staining was used to
confirm equal loading. Blots were probed with mouse anti-PON-1 antifbody. Results are representative of randomized experiments (b) and (d).
Densitometry of PON-1 expression in HDL (c) and sera (e) Results represent means ± SEM * p < 0.05
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concentrations (p < 0.05, Table 2). In black women, the
greater proportion of large HDL was associated with a
younger age (p < 0.05) and higher HDL-C (p < 0.005). Con-
versely, a greater proportion of intermediate HDL was as-
sociated with lower BMI, fat mass, VAT and SAT in white
women. A greater proportion of small HDL was associated
with increased BMI and fat mass in white women.
Discussion
In this preliminary study we aimed to examine whether
ethnicity and obesity may be associated with differences
in HDL functionality and subclass distribution. Our data
showed that, despite lower levels of HDL-C, black women
had higher PON activity levels compared to white women.
In contrast, the activity and protein expression of PAF-AH
was lower in obese black compared to obese white
women. Obesity was not associated with a difference in
the activity of these enzymes, but was associated with a
shift in HDL subclass from large to intermediate and small
HDL, an effect which was largely driven by differences
between normal-weight and obese white women.
The relatively low incidence of myocardial infarction
in the South African black population has long been
thought to be related to an increase in HDL-C levels in
comparison to white populations. However, recent stud-
ies provide evidence for lower HDL-C in South African
black populations compared South African white popu-
lations, despite clear reduced risk of acute myocardial
infarction [6, 18]. Recent research suggests that the qual-
ity of HDL, rather than its quantity, may be a more
important factor to consider as a cardiovascular risk
factor (see review, [23]).
Low serum PON activity levels have been associated with
an increased risk for major adverse cardiovascular events
(MACE), including myocardial infarction and stroke in an
American study [29]. The novel finding of higher PON
activity levels in black women compared to white
women, independent of protein expression levels is in
contrast to other studies in the USA that found that
African Americans had lower or similar PON activity
levels than their white counterparts, despite similar
HDL-C concentrations [30, 31].
Accordingly, we hypothesise that the low rate of
cholesterol-attributable mortality [15], and particularly
the low incidence of myocardial infarction in black pop-
ulations [6] may be explained by higher PON activity
levels. However, this hypothesis would need to be tested,
as a study in a mixed race South African population
found that PON activity was not an accurate predictor
of cardiovascular risk [32].
Our data also indicated that increased PON activity in
black women was not related to a greater amount of
HDL-associated PON-1 protein, which may relate to gen-
etic factors. PON-1 polymorphisms, such as the promotor
region small nucleotide polymorphism (SNP) L-55 M,
causes a reduction in serum PON activity and is much less
frequent in oriental and black populations [33, 34]. Add-
itionally, PON-1 polymorphisms can result in lower activ-
ity with PON-1 serum protein levels unchanged [34].
We showed associations between increased PON activ-
ity and typical markers of risk, including lower LDL and
triglyceride concentrations, which have been reported pre-
viously in an American white young adult population [35].
Of interest was a negative correlation between PON activ-
ity and HDL-C in white but not black women. Failure to
show this association in black women is unexpected
because HDL is associated with PON and has been shown
in other studies to be negatively correlated with HDL-C
[36, 37]. As PON activity remains consistently high in
black women, it is possible that PON activity may be a




















PON Activity Black r = −0.07 r = 0.30 r = 0.26 r = 0.19 r = 0.19 r = 0.29 r = 0.59* r = 0.13 r = 0.66**
White r = −0.40 r = 0.14 r = 0.16 r = −0.25 r = −0.09 r = −0.62*** r = 0.45* r = 0.21 r = 0.28
PAF-AH activity Black r = −0.18 r = −0.44 r = −0.47* r = −0.25 r = −0.48* r = 0.05 r = 0.65*** r = −0.51* r = 0.53*
White r = 0.02 r = 0.42 r = 0.39 r = −0.02 r = −0.10 r = −0.37 r = 0.85*** r = 0.22 r = 0.80***
Large HDL subclass Black r = −0.52* r = −0.32 r = −0.30 r = −0.18 r = −0.31 r = 0.69** r = 0.067 r = −0.19 r = 0.25
White r = −0.31 r = −0.52* r = −0.48* r = −0.48* r = −0.48* r = 0.32 r = −0.49* r = −0.48* r = −0.48*
Intermediate HDL
subclass
Black r = 0.24 r = 0.43 r = 0.41 r = 0.17 r = 0.45 r = −0.64*** r = 0.17 r = −0.15 r = −0.11
White r = 0.40 r = 0.46* r = 0.44* r = 0.58* r = 0.51* r = −0.33 r = 0.36 r = 0.52* r = 0.34
Small HDL subclass Black r = 0.52* r = 0.08 r = 0.08 r = 0.11 r = 0.06 r = −0.29 r = −0.24 r = 0.42 r = −0.25
White r = 0.20 r = 0.52* r = 0.47* r = 0.34 r = 0.41 r = −0.27 r = 0.55** r = 0.40 r = 0.55**
Values are Pearson correlation coefficients
BMI body mass index, VAT visceral adipose tissue, SAT subcutaneous adipose tissue
* p < 0.05, ** p < 0.01, *** p < 0.005
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marker of HDL function in black women, independent of
HDL-C levels.
PAF-AH is another HDL-associated enzyme whose
primary physiological role is maintenance of PAF me-
tabolism and anti-thrombotic functions [38, 39]. Our
data show significantly lower PAF-AH activity in obese
black women compared to obese white women. Overall,
PAF-AH activity was correlated with PAF-AH expres-
sion in HDL while PAF-AH serum expression remained
unchanged amongst the groups. Obese black women
therefore expressed significantly less HDL-associated
PAF-AH than obese white women. Furthermore, re-
duced PAF-AH activity was associated with increased
fat mass and SAT in black women only. PAF-AH is
mainly associated with LDL and a smaller proportion
with HDL, which translate into different physiological
functions of PAF-AH activity [40]. Reduced HDL-
associated PAF-AH activity has been shown to be asso-
ciated with increased risk of cardiovascular disease [41].
Accordingly, our data suggest that reduced HDL-
associated PAF-AH activity in obese black women may
be associated with a reduction in anti-atherogenic HDL
function. However, previous studies have shown that
PON activity modulates HDL-associated PAF-AH activ-
ity [41]. We, therefore, propose that higher PON activ-
ity in obese black women may circumvent reductions in
PAF-AH activity. However, further studies are needed











































































































Fig. 2 PAF-AH activity and protein expression in white and black women. PAF-AH activity of diluted sera was measured at A412 over a 20 min time
interval using the PAF Acetylhydrolase Assay Kit. One unit of activity is defined as 1 μmol of substrate disintegrated per minute (a). Isolated HDL (b–c)
and participant sera (d–e) were run on reducing 12.5 % SDS-PAGE gels and transferred to nitrocellulose membrane. Ponceau S staining was used to
confirm equal loading. Blots were probed with rabbit anti-PAF-AH antibody. Results are representative of randomized experiments (b) and (d).
Densitometry of PAF-AH expression in HDL (c) and sera (e) Results represent means ± SEM * p < 0.05
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Fig. 3 (See legend on next page.)
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Surprisingly, despite the findings regarding PON ac-
tivity, we did not find any significant between group
differences in antioxidant capacity of isolated HDL.
This was similarly found in a study comparing diet in-
duced weight loss in overweight American participants
[42]. We propose that, in the ORAC assay, measure-
ment of total antioxidant capacity may produce differ-
ent results to a specific antioxidant assay such as PON
activity, owing to contributions of additional HDL com-
ponents. Similarly no differences in the expression of
VCAM in HUVEC cells treated with isolated HDL were
found. Since HDL has been shown to reduce expression
of a number of endothelial adhesion molecules, add-
itional markers would need to be used to further con-
firm the findings in this study.
To our knowledge, this is the first report of the distri-
bution of HDL subclasses in an African population. In
our study a similar profile of HDL subclass distribution
was observed between black and white women. How-
ever, obesity was associated with reduced large HDL
subclasses and concomitant higher intermediate and
small subclasses; largely driven by differences between
normal-weight and obese white women. In support of
this finding, markers of increased adiposity, BMI, fat
mass, percentage fat, VAT and SAT correlated with
differences in large and intermediate subclasses in
white but not black women. This shift has been previ-
ously shown in non-African male and female obese
populations, where a decrease in average HDL particle
size and increased concentrations of smaller HDL sub-
classes were reported [43–45]. In this case, HDL subclass
distribution does not explain changes in functionality re-
lated to ethnicity. HDL subclasses were not significantly
different between normal-weight and obese black women,
while HDL subclasses differed by obesity in white women.
A similar trend was observed in LDL subclasses in the
same population of women, where differences in LDL sub-
class in normal-weight and obese women were observed
in white but not black women [18].
Longitudinal data on a black South African cohort also
indicate that despite increases in weight, HDL-C con-
centrations remained consistently low in black women
[46]. In spite of this, we show that black women display
improved HDL antioxidant functionality in comparison
to white women, indicating the importance in measure-
ment of HDL quality instead of total HDL cholesterol
levels.
Conclusions
We acknowledge that the small sample size limits the
conclusions which can be drawn, however our data
indicate that obesity and ethnicity affect HDL function-
ality and HDL subclass. We, therefore, suggest that
future studies examining the association between HDL
and cardiovascular risk should focus on examining the
role of HDL subclass and functionality. We considered
a number of functionality assays in this study, however,
additional measures such as reverse cholesterol efflux
can be considered in similar studies in the future. Lon-
gitudinal studies are required to determine if HDL sub-
class and function are indeed important risk factors for
cardiovascular disease.
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Additional file 1: Figure S1. Paraoxonase protein expression in white and
black women. Isolated HDL (a–c) and serum (d–f) from each participant was
randomly loaded and run on reducing 12.5 % SDS-PAGE gels and transferred
to nitrocellulose membrane. Ponceau S staining was used to confirm
equal loading. Blots were probed with mouse anti-PON-1 antibody. WN
=White normal-weight. WO =White obese. BN = Black normal weight.
BO = Black obese. Figure S2. PAF-AH protein expression in white and
black women. Isolated HDL (a–c) and serum (d–f) from each participant
was randomly loaded and run on reducing 12.5 % SDS-PAGE gels and
transferred to nitrocellulose membrane. Ponceau S staining was used to
confirm equal loading. Blots were probed with rabbit anti-PAF-AH antibody.
WN=White normal-weight. WO=White obese. BN = Black normal weight.
BO = Black obese. Figure S3. Vascular Cell Adhesion Molecule (VCAM)
expression in endothelial cells treated with HDL. HUVEC cells were treated
overnight with 10 μg/ml subject HDL. Cells were exposed to 20 ng/ml
tumour necrosis factor (TNF) for 8 h. Cell lysates were harvested and stored
in RNAprotect reagent prior to RNA extraction, followed by cDNA synthesis
and quantitative real time PCR. Results are presented relative to a no-HDL
treatment control. Results are means of 3 independent experiments ± SEM.
Figure S4. Antioxidant capacity of isolated HDL. Isolated subject HDL was
diluted in phosphate buffer and measured using the Oxygen Radical
Absorbance Capacity (ORAC) assay. (PDF 403 kb)
Abbreviations
BMI: body mass index; DTNB: 5, 5'-dithio-bis-(2-nitrobenzoic acid); HDL-C: high-
density lipoprotein-cholesterol; HUVEC: human umbilical vein endothelial
cells; LDL: low-density lipoprotein; PAF-AH: platelet activating factor
acetylhydrolase; PON: paraoxonase; SAT: subcutaneous adipose tissue;
(See figure on previous page.)
Fig. 3 Distribution of HDL subclasses in participant sera. Subject sera was analysed using the Lipoprint® system and analysed using Lipoware software.
Representative scan (a) and scan result (b) of Liposure control indicating HDL subclass bands. Representative scan results from white and black obese
and normal-weight women (c–f). Percentages of large, intermediate and small HDL subclasses (g). VLDL – Very low density lipoprotein. Results represent
means ± SEM. * p< 0.05
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SDS-PAGE: SDS-polyacrylamide; TNF- α: tumour necrosis factor alpha;
VAT: visceral adipose tissue; VCAM: vascular cell adhesion molecule;
VEGF: vascular endothelial growth factor.
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